AIT-082. Cognition enhancer

Drugs of the Future

Volumn 22, Issue 9, 1997, Pages 945-947

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (6 OXO 1,6 DIHYDRO 9H PURIN 9 YL)PROPIONAMIDO]BENZOIC ACID; BENZOIC ACID DERIVATIVE; NOOTROPIC AGENT; PROPIONAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COGNITION; DRUG ACTIVITY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; REVIEW;

EID: 1842373335     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.09.423213     Document Type: Review

References (15)

1. Glasky, A.J. Multi-functional pharmaceutical cpds. and methods of use. WO 9114434.
2. Glasky, A.J., Ritzmann, R.F., Melchior, C.L., Hindley, S., Gysbers, J.W., Rathbone, M.P. Effect of AIT-082 on neuritogenesis in vitro and working memory in vivo. Soc Neurosci Abst 1993, 19(Part 1): Abst 24.8.
3. Glasky, A.J., Ritzmann, R.F., Melchior, C.L., Hindley, S., Gysbers, J.W., Middlemiss, P., Rathbone, M.P. AIT-082 restores age-induced memory deficits and modulates neuritogenesis through a carbon monoxide/guanylate cyclase mechanism. Can J Physiol Pharmacol 1994, 72(Suppl. 1): Abst P17.2.10.
4. Glasky, A.J., Kirat, S., Middlemiss, P.J., Gysbers, J.W., Rathbone, M.P. A novel purine derivative AIT-082 increases the synthesis of NGF, FGF-2 and NT-3 mRNA in astrocytes. Soc Neurosci Abst 1995, 21(Part 1): Abst 125.10.
5. Middlemiss, P.J., Glasky, A.J., Rathbone, M.P., Werstuik, E., Hindley, S., Gysbers, J. AIT-082, a unique purine derivative, enhances nerve growth factor mediated neunte outgrowth from PC12 cells. Neurosci Lett 1995, 199: 131-4.
6. Glasky, A., Pirzadeh, B., Ritzmann, R.F. AIT-082, a purine derivative which modulates working memory in normal mice and mice with age-induced memory deficits. Neurobiol Aging 1992, 13(Suppl. 1): Abst 442.
7. Ritzmann, R.F., Prisecaru, I., Melchior, C.L., DeLeon-Jones, F., Glasky, A.J. Effect of AIT-082 on ethanol-induced amnesia and behavior. Soc Neurosci Abst 1994, 20(Part 2): Abst 721.12.
8. Glasky, A.J., Melchior, C.L., Pirzadeh, B., Heydari, N., Ritzmann, R.F. Effect of AIT-082, a purine analog, on working memory in normal and aged mice. Pharmacol Biochem Behav 1994, 47: 325-9.
9. Ritzmann, R.F., Glasky, A.J., Prisecaru, I., Rathbone, M.P. AIT-082 delays the onset of age-induced working memory loss. Soc Neurosci Abst 1995, 21(Part 2): Abst 377.13.
10. Rathbone, M.P., Glasky, A.J., Prisecaru, I., Santos, S., Rafi, K., Crocker, C. Neurotrophic effects of the hypoxanthine derivative AIT-082 on working memory. Drug Develop Res 1996, 37(3): 191.
11. Glasky, A., Ritzmann, R., Rathbone, M. Neurotrophins, growth factors and mimetic agents as neuroprotectors in the treatment of Alzheimer disease. 4th Int Nice/Springfield Symp Adv Alzheimer Ther (April 10-14, Nice) 1996, 41.
12. Ritzmann, R.F., Glasky, A., Steinberg, A., Melchior, C.L. The interaction of ethanol with the cognitive enhancers tacrine, physostigmine, and AIT-082. J Gerontol 1994, 49: B51-3.
13. NeoTherapeutics' files Investigational New Drug application with FDA for lead compound, AIT-082. NeoTherapeutics, Inc. Press Release 1997, April 2.
14. First patients dosed in phase I study on new class of drugs for Alzheimer's disease - AIT-082 trials will be conducted by the Alzheimer's Disease Cooperative Study. NeoTherapeutics, Inc. Press Release 1997, July 14.
15. New class of Alzheimer's drug cleared for clinical testing in Canada. NeoTherapeutics' lead compound to begin phase I/II trial within 30 days. NeoTherapeutics, Inc. Press Release 1997, March 6.